Fig. 7From: Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysisSensitivity analysis of PFS was employed to explore sources of heterogeneity. Heterogeneity declined from I2 = 44% to I2 = 9% when the study performed by Noda et al. was excludedBack to article page